TX-SPINALCYTE,-LLC
15.5.2019 16:20:11 CEST | Business Wire | Press release
SpinalCyte, LLC, a clinical stage regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced a new comprehensive resource to raise awareness of the potential benefits of fibroblasts and provide a growing knowledge base for this promising regenerative medicine technology.
The company’s website, www.spinalcyte.com , now features company and independent research studies demonstrating the potential of this new cell source for disc repair and other disease pathways.
“Fibroblasts hold significant advantages over mesenchymal stem cells,” said Dr. Thomas Ichim, Chief Scientific Officer of SpinalCyte and author of an analysis comparing the two cell sources published in the Journal of Translational Medicine . “As we and other leading researchers continue to advance the science in this field, our website will be the best place to find the latest and most up-to-date information on the healing power of fibroblasts.”
SpinalCyte is the leader in the field of HDF therapy with 52 U.S. and international patents issued and 85+ patents pending focused on the clinical utility of fibroblasts.
“Fibroblasts are the regenerative cell source of the future,” said Pete O’Heeron, Chief Executive Officer of SpinalCyte. “The breadth of our intellectual property demonstrates the versatility of this technology and positions us as the unquestioned frontrunner in this emerging sector. We look forward to presenting new research from around the globe highlighting the promise of fibroblasts.”
About Degenerative Disc Disease
Degenerative disc disease (DDD) is a condition in which a patient’s spinal disc breaks down and can begin to collapse. It is estimated that 85% of people over the age of 50 have evidence of disc degeneration and over 1.3 million procedures a year are performed to treat the disease. The most common treatments for patients with DDD are either discectomy or spinal fusion. Discectomy is the partial or full removal of the degenerated disc to decompress and relieve the nervous system but can cause long term spinal pain. In a spinal fusion procedure, the entire disc is removed and the two adjacent vertebrae are fused together. It often increases strain on the adjacent discs and surrounding tissues leading to further degeneration.
About CybroCell
CybroCell is the first off-the-shelf allogenic human dermal fibroblast (HDF) product for the treatment of degenerative disc disease. SpinalCyte’s Phase 1/Phase 2 clinical trial for injected human dermal fibroblasts in the treatment of DDD demonstrated after 18 months, patients injected with CybroCell had sustained improvement in pain relief and increased back mobility.
About SpinalCyte
Based in Houston, Texas, SpinalCyte, LLC, is a regenerative medicine company developing an innovative solution for spinal disc replacement using human dermal fibroblasts. Currently, SpinalCyte holds 52 U.S. and international issued patents and has filed for an additional 85+ patents pending and issued across a variety of clinical pathways, including disc degeneration, cancer, diabetes, liver failure and heart failure. SpinalCyte represents the next generation of medical advancement in cell therapy. Visit www.spinalcyte.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005305/en/
Contact:
David Schull or Ned Berkowitz Russo Partners LLC 858-717-2310 646-942-5629 david.schull@russopartnersllc.com ned.berkowitz@russopartnersllc.com
Clinical Contact: info@spinalcyte.com
Link:
Social Media:
https://www.facebook.com/LibertyStarLBSR/#!/pages/Liberty-Star-Uranium-Metals-Corp/135810219778400?r
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GN Corporation’s academic event NCRM NICHE commemorates 21st anniversary of NCRM.4.11.2026 07:10:00 CET | Press release
Kamineni Institute, Hyderabad wins XXI Fujio Cup Quiz on stem cells and regenerative medicine. The XXI edition of Fujio Cup Quiz (FCQ) in NCRM NICHE 2026, hosted by GN Corporation, Japan and Nichi-In centre for Regenerative Medicine (NCRM), was won by Sameer Kumar Reddy and Chava Aravind Kumar from Kamineni Academy of Medical Sciences and Research Centre, Hyderabad, India. Ganga Anand Desai and Amith Mathew from Sri Ramachandra Institute of Higher Education and Research, Chennai, India, came runners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103893272/en/ NCRM NICHE is held every year in October since 2006, past 21 years. In 2026, in the active knowledge gaining event, Fujio Cup Quiz, 80 teams from institutes of biotechnology, medicine, veterinary, dentistry and allied health sciences participated, among whom four got to the finals. Kamineni Academy of Medical Sciences, Hyderabad, India won the prestigious Fujio Cup.
Global Consumer Trends 2027: Trust, Transparency and Control Take Centre Stage4.11.2026 06:01:00 CET | Press release
Consumers are no longer placing full trust in brands, technology or the future itself. As uncertainty becomes a permanent feature of daily life, greater value is being placed on reliability, transparency and immediate proof of value. Euromonitor International's Top Global Consumer Trends 2027 report finds consumers seeking greater control as uncertainty reshapes consumer behaviour. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103010032/en/ Euromonitor's Top global consumer trends 2027 Drawing on insights from Passport, Euromonitor International's AI-powered market intelligence platform, the report finds consumers looking for balance and control in a world they no longer expect to be certain. Across markets, consumers are placing greater value on reliability, transparency, community and immediate, tangible benefits. “Consumers are no longer simply buying products or services; they're looking for confidence," said Ali Ang
H2SITE Selected for EU Innovation Fund Support to Advance Industrial-Scale Ammonia Cracking in Rotterdam4.11.2026 06:00:00 CET | Press release
The proposed Rotterdam facility would advance the industrial deployment of H2SITE’s hydrogen technology, with a planned production capacity of 20 tons of hydrogen per day. H2SITE has been selected for support from the European Union’s Innovation Fund for the development of an industrial-scale ammonia cracking project in Rotterdam, subject to the formalisation of the grant agreement. The selection marks an important milestone in the company’s work to scale its technology and support the decarbonisation of hard-to-abate industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103379287/en/ Aerial view of the Botlek in Rotterdam. Photo: T.W. van Urk / Shutterstock The project aims to recover and purify hydrogen from imported ammonia close to industrial consumption centres, advancing the industrial deployment of H2SITE’s technology. H2SITE is working closely with industrial stakeholders in Rotterdam to define the project’s
The Estée Lauder Companies Announces Fiscal 2030 Ambition at Its Capital Markets Experience: China Ecosystem Immersion Event4.11.2026 06:00:00 CET | Press release
Sustainable Mid-Single-Digit Organic Net Sales Growth through Fiscal 2030 Adjusted Operating Margin of 16.5%-18.5% in Fiscal 2030Double-Digit Adjusted EPS Growth through Fiscal 2030 The Estée Lauder Companies Inc. (NYSE: EL) today announced its fiscal 2030 ambition at its Capital Markets Experience: China Ecosystem Immersion event in Shanghai, China. Stéphane de La Faverie, President and Chief Executive Officer, and Akhil Shrivastava, Executive Vice President and Chief Financial Officer, outlined the Company’s targets, including its plans to build on the progress of its Beauty Reimagined strategic vision and the execution of its One ELC operating model to deliver sustainable growth while continuing to drive stronger operating leverage and expanded profitability. “We are now entering a new chapter, moving beyond restoring growth to accelerating sustainable, profitable growth and creating long-term value. Our fiscal 2027 outlook reflects this momentum, with accelerating organic sales gro
FPT, Airbus’ Skywise, and Vietnam Airlines Partner to Advance AI-Powered Airline Operations4.11.2026 05:21:00 CET | Press release
FPT, Vietnam Airlines and Skywise, Airbus' digital services company, have signed a Memorandum of Understanding (MoU) to explore the development of AI-powered services. By combining Vietnam Airlines’ operational expertise and data, insights from the Skywise platform, and FPT’s capabilities in aviation technology, systems integration and AI engineering, the collaboration will identify practical AI use cases that could enhance performance, strengthen resilience and support better-informed decision-making. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103646801/en/ The MOU was announced at the Vietnam Aerospace Forum (VAF) in Hanoi on 4 November 2026. The programme will initially focus on fleet reliability, technical operations and disruption management. By combining Skywise’s insights with maintenance planning, parts readiness and flight schedules, the parties will explore AI applications to improve aircraft availability an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom